Unicycive Therapeutics (UNCY)

• Market cap: $81.6M
• 1 day: 3.12%
• 5 days: -2.53%
• 1 month: -0.22%
• 3 months: 13.79%
• 6 months: -27.47%
• Year to date: -41.67%
• 1 year: -18.95%
• 5 years: -92.1%
• 10 years: -92.1%
• Sector: Healthcare
• Industry: Biotechnology

About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Employees: 22